trending Market Intelligence /marketintelligence/en/news-insights/trending/wuDkZGF1EbweO5QwrlU7GQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Neovasc raising $5M from common stock offering to fund heart device development

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Neovasc raising $5M from common stock offering to fund heart device development

Neovasc Inc. priced an underwritten public offering of 11,111,111 common shares at 45 cents apiece to raise gross proceeds of about $5 million.

The Richmond, British Columbia-based medical device company expects to raise about $4.3 million in net proceeds from the offering.

Funds from the offering will cover development and commercial activities for Neovasc Reducer. The company will also use the proceeds from the offering to support the development of Tiara as well as for general corporate purposes and working capital.

Neovasc Reducer is used to treat inadequate blood flow to the heart as a result of refractory angina, while Tiara is being developed to treat mitral valve disease, a condition that disturbs the blood flow in the left side of the heart and can lead to heart failure and death.

Neovasc expects to close the offering on or about March 15, subject to closing conditions, including approvals and listing of common shares on the Toronto Stock Exchange and the Nasdaq Capital Market.

H.C. Wainwright & Co. is the sole book-running manager for the offering.